Stocky turns companies like BLLN into a fun, safe way to learn investing — a virtual portfolio, live scores & charts, and real analyst data, with no real money.
Try Stocky free →Cautious. Biomerica's 65/100 Growth Compounder Score reflects solid diagnostic test expansion, but a 145× forward P/E demands flawless execution amid structural headwinds: >90% revenue concentration in molecular diagnostics plus heavy payor reimbursement dependence (Medicare/Medicaid) create meaningful vulnerability to pricing pressure and regulatory shifts. Leadership alignment (62/100) is moderate, lacking outsized founder commitment. Growth must substantially accelerate to justify valuation.
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for BLLN:
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 54/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates BLLN (BLLN) at 54/100 — below the bar Stocky looks for. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Cautious. Biomerica's 65/100 Growth Compounder Score reflects solid diagnostic test expansion, but a 145× forward P/E demands flawless execution amid structural headwinds: >90% revenue concentration in molecular diagnostics plus heav
BLLN's current Stocky Verdict is 54/100, placing it in the "Cautious" band. This composite combines a 65/100 Compounder score, 62/100 Leadership, Moat rating, and analyst signal.
Stocky hasn't finalised a Moat Score for BLLN yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
BLLN scores 62/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
BLLN's Vulnerability Profile scores 50/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to BLLN.
Sign up free and unlock the full analysis on BLLN — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
This page is just a preview. Open the live, interactive version for the full picture:
Or jump straight to the interactive dashboard for BLLN in the app.
